Occupational exposure to cisplatin/oxaliplatin during Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)?

被引:30
|
作者
Ametsbichler, Paul [1 ]
Boehlandt, Antje [1 ]
Nowak, Dennis [1 ]
Schierl, Rudolf [1 ]
机构
[1] Ludwig Maximilians Univ Munchen, Inst & Clin Occupat Social & Environm Med, Univ Hosp, Ziemssenstr 1, D-80336 Munich, Germany
来源
EJSO | 2018年 / 44卷 / 11期
关键词
PIPAC; Occupational exposure; Environmental monitoring; Platinum; Contamination; Peritoneal carcinomatosis; HEALTH-CARE WORKERS; BODY-SURFACE-AREA; PERITONEAL CARCINOMATOSIS; ANTINEOPLASTIC DRUGS; CONTAMINATION; SAFETY; PROGNOSIS; PLATINUM; CANCER; RISKS;
D O I
10.1016/j.ejso.2018.05.020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) is a new promising treatment for patients with peritoneal carcinomatosis. It is supposed to provide a higher local drug concentration and deeper penetrate into the tumor tissue compared to systemic chemotherapy or hyperthermic intraperitoneal chemotherapy perfusion (HIPEC). Due to the application of cytotoxic drug aerosols within the operating room (OR), concern has been raised regarding the occupational exposure risk of the involved OR staff. Materials and Methods: In this study, an OR workplace monitoring was performed during 14 PIPAC procedures in two hospitals by collecting air samples (n = 14) during PIPAC and wipe samples (n = 223) before and after PIPAC: 56 samples from the OR floor, 84 from the injector, 28 from trocars and 55 from gloves. All samples were analyzed for platinum (Pt). Results: While air Pt concentrations were below 3.1 pg/m(3), surface contaminations widely varied between 0.01 pg/cm(2) and 1733 pg/cm(2) (median 1.04 pg/cm(2)), with substantial Pt concentrations on injector parts (i.e. syringe holder) and trocars. Floors and particularly injectors were often higher contaminated before compared to after PIPAC, probably due to inefficient cleaning or cross-contamination. Glove samples taken after different tasks ranged between 0,04 and 423 pg/cm(2) (median 0.58 pg/cm(2)). Conclusion: Contamination on various OR surfaces widely ranged and can lead to a distribution of cytotoxic drug residues. However, the air contamination was very low. The results indicate that PIPAC performance seems to be possible with low occupational exposure risk, but adequate safety and cleaning standards for PIPAC must be developed and monitored. (C) 2018 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
引用
收藏
页码:1793 / 1799
页数:7
相关论文
共 50 条
  • [41] Initial experience of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a French hyperthermic intraperitoneal chemotherapy (HIPEC) expert center
    C. Ceribelli
    T. Debs
    A. Chevallier
    M. A. Piche
    J. M. Bereder
    Surgical Endoscopy, 2020, 34 : 2803 - 2806
  • [42] Initial experience of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a French hyperthermic intraperitoneal chemotherapy (HIPEC) expert center
    Ceribelli, C.
    Debs, T.
    Chevallier, A.
    Piche, M. A.
    Bereder, J. M.
    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2020, 34 (06): : 2803 - 2806
  • [43] Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin or oxaliplatin for peritoneal metastasis from pancreatic adenocarcinoma and cholangiocarcinoma
    Di Giorgio, Andrea
    Sgarbura, Olivia
    Rotolo, Stefano
    Schena, Carlo Alberto
    Bagala, Cinzia
    Inzani, Frediano
    Russo, Andrea
    Chiantera, Vito
    Pacelli, Fabio
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [44] Safety and preliminary efficacy of electrostatic precipitation during pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable carcinomatosis
    Willaert, W.
    Van de Sande, L.
    Van Daele, E.
    Van De Putte, D.
    Van Nieuwenhove, Y.
    Pattyn, P.
    Ceelen, W.
    EJSO, 2019, 45 (12): : 2302 - 2309
  • [45] PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases
    Kim, Guowei
    Tan, Hon Lyn
    Sundar, Raghav
    Lieske, Bettina
    Chee, Cheng Ean
    Ho, Jingshan
    Shabbir, Asim
    Babak, Maria, V
    Ang, Wee Han
    Goh, Boon Cher
    Yong, Wei Peng
    Wang, Lingzhi
    So, Jimmy B. Y.
    CLINICAL CANCER RESEARCH, 2021, 27 (07) : 1875 - 1881
  • [46] Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Gastric Cancer Peritoneal Metastases: Results from the Lithuanian PIPAC Program
    Luksta, Martynas
    Bausys, Augustinas
    Gendvilaite, Neda
    Bickaite, Klaudija
    Rackauskas, Rokas
    Paskonis, Marius
    Luksaite-Lukste, Raminta
    Ranceva, Anastasija
    Stulpinas, Rokas
    Brasiuniene, Birute
    Baltruskeviciene, Edita
    Lachej, Nadezda
    Bausiene, Juste
    Poskus, Tomas
    Bausys, Rimantas
    Tulyte, Skaiste
    Strupas, Kestutis
    CANCERS, 2024, 16 (17)
  • [47] Selection Criteria for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatment in Patients with Peritoneal Metastases
    Balmer, Aurelie
    Clerc, Daniel
    Toussaint, Laura
    Sgarbura, Olivia
    Taibi, Abdelkader
    Hubner, Martin
    Teixeira Farinha, Hugo
    CANCERS, 2022, 14 (10)
  • [48] Correction to: Comparison between microcatheter and nebulizer for generating Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
    Laura Toussaint
    Yaroslav Sautkin
    Barbara Illing
    Frank‑Jürgen Weinreich
    Giorgi Nadiradze
    Alfred Königsrainer
    Dörte Wichmann
    Surgical Endoscopy, 2021, 35 : 4901 - 4901
  • [49] Pressurized intraperitoneal aerosol chemotherapy (PIPAC): updated systematic review using the IDEAL framework
    Baggaley, Alice E.
    Lafaurie, Guillaume B. R. C.
    Tate, Sophia J.
    Boshier, Piers R.
    Case, Amy
    Prosser, Susan
    Torkington, Jared
    Jones, Sadie E. F.
    Gwynne, Sarah H.
    Peters, Christopher J.
    BRITISH JOURNAL OF SURGERY, 2023, 110 (01) : 10 - 18
  • [50] Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin, Cisplatin, and Doxorubicin in Patients with Peritoneal Carcinomatosis: An Open-Label, Single-Arm, Phase II Clinical Trial
    De Simone, Michele
    Vaira, Marco
    Argenziano, Monica
    Berchialla, Paola
    Pisacane, Alberto
    Cinquegrana, Armando
    Cavalli, Roberta
    Borsano, Alice
    Robella, Manuela
    BIOMEDICINES, 2020, 8 (05)